Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To discover, develop and deliver affordable and safe antimalarial drugs for vulnerable populations
Subscribe to our email newsletter
Medicines for Malaria Venture (MMV) has received its fifth grant from the Bill & Melinda Gates Foundation, to fund its research and development pipeline with an additional $115m over the next 5 years.
Reportedly, the foundation supports research to eradicate malaria using all the health tools needed, from drugs, vaccines, diagnostics and pesticides to long-lasting insecticide-treated bed-nets. With the provision of this grant, the cumulative funding raised and pledged to MMV from 14 public and private donors is $470 million.
Chris Hentschel, president and CEO at MMV, said: “This substantial grant is a very welcome, indeed transformative, addition to those recently announced from other sources. It will underpin financially what we are seeking to achieve in our new business plan and validate it as an excellent development investment. Despite these times of financial turbulence we can enter our 10th year not just with a clear vision but with the means to implement it. We are extremely grateful, and proud of our long and sustained association with the Bill & Melinda Gates Foundation. We appreciate the acknowledgement of our work in the field of research and development of effective antimalarials.”
Timothy Wells, CSO at MMV, said: “This funding arrives at a critical time for us. Over the last few months, with our partners we have launched a high-quality antimalarial designed specially for children (Coartem Dispersible), submitted another antimalarial to the EMEA for regulatory approval (Eurartesim), and are in the process of collating the regulatory dossier for a third antimalarial (Pyramax). With our partners, we have built a portfolio of more than 50 new projects of which ten are in clinical development. With the emergence of resistance to Artemisinin in Cambodia, it’s clear that the ambitious goal of malaria eradication will require a wide range of new medicines. The new grant from the Foundation will enable MMV to continue the development of the next generation of antimalarial medicines.”